ArticleThe lancet. Psychiatry2021
Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark.
Article in The lancet. Psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Genetic and phenotypic similarity across major psychiatric disorders: a systematic review and quantitative assessment.Translational psychiatry · 2024Pooled it
- The Impact of Pre-Existing Psychiatric Disorders on Gastric Cancer Stage and Mortality in Older Adults.Cancer medicine · 2026Article
- Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Splitting schizophrenia: divergent cognitive and educational outcomes revealed by genomic structural equation modelling.Molecular psychiatry · 2026Article
- Hippocampal small RNAs from patients with schizophrenia induce specific cognitive and neural phenotypes in mice.Cell death discovery · 2026Article
- Identifying transdiagnostic neurobiomarkers for precision major psychiatric disordersJournal of translational internal medicine · 2026Article
- Integrative neuroimmunology reveals leukocyte-expressing PAX6 as a critical predictor of major depressive disorder.Translational psychiatry · 2025Article
- Vocational Rehabilitation in Young Adults With Incident Schizophrenia-A Danish Retrospective Cohort Study.Early intervention in psychiatry · 2025Article
- From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.The international journal of neuropsychopharmacology · 2025Review
- Nationwide study of emergency care quality for patients with substance use disorders and dual diagnoses across three distinct patient populations.BMC psychiatry · 2025Article
- Can artificial intelligence be the future solution to the enormous challenges and suffering caused by Schizophrenia?Schizophrenia (Heidelberg, Germany) · 2025Review
- The Challenging Problems of Cancer and Serious Mental Illness.Current psychiatry reports · 2025Review
- Case series of patients with early psychosis presenting hypoperfusion in angular gyrus and self-disturbance: Implication for the sense of agency and schizophrenia.Neuropsychopharmacology reports · 2024Article
- Evaluation of routine health monitoring for metabolic disorders in patients with serious mental illness on psychotropic medications: a study from Ethiopia.BMC psychiatry · 2024Article
- Educational differences in years lived with disability due to mental and substance use disorders: a cohort study using nationwide Norwegian and Danish registries.BMC public health · 2024Article
- Overshadowing and salience attribution in relation to cannabis use.Schizophrenia research. Cognition · 2024Article
- Disease burden of mental disorders among children and adolescents considering both co-morbidities and suicide in Northeastern China.BMC public health · 2024Article
- Assessing Cannabis Use in People with Psychosis.Cannabis and cannabinoid research · 2024Review
- Systemic inflammatory biomarkers in Schizophrenia are changed by ECT administration and related to the treatment efficacy.BMC psychiatry · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMental disorders account for a substantial proportion of the years lived with disability (YLDs) globally. These estimates have generally been calculated top down based on summary statistics. The aim for this study was to calculate YLDs and a novel related measure, Health Loss Proportion (HeLP), for 18 mental and substance use disorders, based on person-level register data (bottom up).
methodsA cohort of 6 989 627 Danish residents (5·9% had a diagnosis of a mental or substance use disorder registered in the Danish Psychiatric Central Research Register) was investigated. YLDs (the duration of disease multiplied by a disability weight) were calculated for the disorder of interest and for comorbid mental and substance use disorders. HeLPs were estimated as YLDs associated with an index disorder and comorbid mental and substance use disorders divided by person-years at risk in persons with the index disorder. All analyses were adjusted for mental and substance use comorbidity using a multiplicative model of disability weights.
findingsMajor depressive disorder was the most prevalent disorder, although schizophrenia was the leading cause of YLDs in both sexes combined (YLDs 273·3 [95 % CI 232·3-313·6] per 100 000 person-years). People diagnosed with schizophrenia lost the equivalent of 73% (63-83%) of healthy life per year due to mental and substance use disorders, the largest HeLP of all mental and substance use disorders. Comorbidity of mental and substance use disorders accounted for 69-83% of HeLPs in people with either cannabis use disorders, other drug use disorder and ADHD. By contrast, comorbidity explained 11-23% of the HeLPs in people with autism spectrum disorders, conduct disorder, and schizophrenia.
interpretationSubstantial variation in disability was observed across age, sex, and disorders. The new HeLP metric provides novel details of the contribution of comorbidity to the disability associated with mental and substance use disorders.
fundingThe Danish National Research Foundation, Queensland Government Department of Health, European Union's Horizon 2020, Lundbeck Foundation, Stanley Medical Research Institute. TRANSLATION: For the Danish translation of the abstract see Supplementary Materials section.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.